Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease | Zendy

Koon Teo | Zendy; Larry B. Goldstein | Zendy; Bernard R. Chaitman | Zendy; Shan Grant | Zendy; William S. Weintraub | Zendy; David C. Anderson | Zendy; Cathy Sila | Zendy; Salvador CruzFlores | Zendy; Robert J. Padley | Zendy; William J. Kostuk | Zendy; William E. Boden | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease

Author(s) -

Koon Teo,

Larry B. Goldstein,

Bernard R. Chaitman,

Shan Grant,

William S. Weintraub,

David C. Anderson,

Cathy Sila,

Salvador CruzFlores,

Robert J. Padley,

William J. Kostuk,

William E. Boden

Publication year - 2013

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.113.001529

Subject(s) - medicine , niacin , stroke (engine) , ischemic stroke , disease , cardiology , ischemia , mechanical engineering , engineering

In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental benefit, despite increases in high-density lipoprotein cholesterol. Preliminary analysis based on incomplete end point adjudication suggested increased ischemic stroke risk among participants randomized to ERN.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research